Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must be at least 40 years old~* Participants with Lp(a) ≥175 nmol/L at randomization, measured at the central laboratory.~* High risk for cardiovascular events defined as documented coronary artery disease (CAD), stroke, or peripheral artery disease or atherosclerotic cardiovascular disease (ASCVD) risk equivalents (familial hypercholesterolemia or type 2 diabetes).~* Participants on the following medications according to local practice must be on a stable regimen for at least 4 weeks prior to randomization and expected to remain on a stable regimen through the end of the post-treatment follow-up period.~  * lipid-lowering drugs~ * testosterone, estrogens, anti-estrogens, progestins, selective estrogen receptor modulators, or growth hormone~* Have a body mass index within the range 18.5 to 40 kilogram/square meter (kg/m²), inclusive.~* Males who agree to use highly effective or effective methods of contraception may participate in this trial.~* Women of childbearing potential (WOCBP) who agree to use highly effective or effective methods of contraception and women not of childbearing potential (WNOCBP) may participate in this trial.~Exclusion Criteria:~* Have a history or presence of an underlying disease, or surgical, physical, medical, or psychiatric condition that, in the opinion of the investigator, would potentially affect participant safety within the study or interfere with participating in or completing the study or with the interpretation of data.~* Any of the following, or other events indicating unstable medical condition in the opinion of the investigator, within 3 months of randomization:~  * major surgery~ * coronary, carotid, or peripheral arterial revascularization~ * stroke or transient ischemic attack~ * myocardial infarction or unstable angina~ * acute limb ischemia~* Have, in the 6 months prior to day 1, uncontrolled Type 1 or Type 2 diabetes~* Have uncontrolled hypertension

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LY3473329 Dose 1 (Type: EXPERIMENTAL): Participants will receive LY3473329 orally.
- LY3473329 Dose 2 (Type: EXPERIMENTAL): Participants will receive LY3473329 orally.
- LY3473329 Dose 3 (Type: EXPERIMENTAL): Participants will receive LY3473329 orally.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo orally.

Based on this trial design, predict the completion outcome and termination type (if applicable).